CSF2 and melanoma: Overall, we conclude that, although CpG ± GM-administered patients showed significantly lower numbers of SLN metastases, additional measures to minimize loco-regional Treg activity might optimize the clinical efficacy of CpG and GM-CSF as immune-potentiating agents for early-stage melanoma patients.